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ABSTRACT
 
Behavioral effects of dopamine receptors were assessed in
 
11- and 17-day-old rat pups using irreversible dopamine
 
antagonist, EEDQ. In Experiment 1, the locomotor activity
 
and sniffing behavior of 11- and 17-day-olds was assessed
 
after treatment with the nonselective dopamine receptor
 
agonist, NPA (6.00, 0.01, 0.1, 1.0, and 5.0 mg/kg). Testing
 
sessions began 5-min after NPA treatment on three test days.
 
In Experiment 2, 10- and 16-day-old rat pups received a
 
single dose of EEDQ (7.5 mg/kg) or vehicle after dopamine
 
receptors were left either unprotected or protected using a
 
combination of sulpiride (100.0 mg/kg) and SCH 23390 (1.0
 
mg/kg). NPA (0.00, 0.01, or 5.0 mg/kg) was then
 
administered to rat pups 24, 48, and 96 hours after EEDQ
 
treatment. Results from Experiment 1 suggest that NPA did
 
not increase activity in 11-day-old pups; whereas, 17-day­
olds showed an increase in activity, with 0.01 mg/kg NPA
 
producing the greatest effect. NPA produced a dose-

dependent increase in sniffing in both aged pups. In
 
Experiment 2, EEDQ did not affect the locomotor activity or
 
sniffing of 11-day-old pups; whereas, 17-day-olds showed
 
some enhancement of locomotor activity and sniffing after
 
EEDQ treatment. Results indicate that the response of
 
preweanling and adult rats to EEDQ is fundamentally
 
different. Possible explanations are discussed.
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INTRODUCTION
 
Dopamine systems have been implicated in a number of
 
important functions including attention, learning, and
 
movement. Dopamine's role in the motor system has linked it
 
to conditions involving excessive, exaggerated, or bizarre
 
involuntary movements, such as in Huntington's chorea,
 
tardive dyskinesia, epilepsy, and Parkinson's disease. L-

Dopa, a precursor to dopamine, increases the synthesis and
 
release of dopamine in Parkinson's patients, thereby
 
alleviating symptoms of tremors, difficulty in initiating
 
movement, loss of balance, and rigidity of limbs. Chronic
 
administration of L-Dopa, as well as high doses of
 
amphetamine, cocaine, and other dopamine agonists produce
 
schizophrenic-like symptoms, such as hallucinations,
 
delusions, and disorganized thinking. Drugs that block
 
dopamine activity decrease symptoms of schizophrenia,
 
suggesting that schizophrenia may be caused by an increase
 
in dopaminergic functioning. Developmental disorders, such
 
as Tourette's syndrome and Lesch-Nyhan disease have also
 
been associated with dopamine systems (Calne, 1978, 1980;
 
Clark & White, 1987; Cote & Crutcher, 1985; Mason, 1984).
 
The important roles of dopamine systems, as well as the
 
severity of illnesses linked to dopamine systems, have
 
prompted many researchers to investigate dopamine
 
functioning. Pharmacological studies have led to the
 
discovery of many drugs which exert various effects on
 
dopamine systems, drugs that help alleviate symptoms of
 
disease and neurological disorders, as well as those that
 
are used to provide an understanding of dopaitiinergic
 
functioning. Ontogenetic studies also provide important
 
information on dopamine systems and their development.
 
Studies of the developing dopamine system contribute to an
 
understanding of normal functioning as well as abnormal
 
functioning. Information on how these systems mediate
 
behavior in the developing animal also increase knowledge of
 
dopaminergic systems, which is the focus of the current
 
study.;
 
In studying the ontogeny of the nigrostriatal dopamine
 
system (a major ascending pathway in the CNS), several
 
issues need to be addressed: 1. the basic biology of
 
dopamine Systems; 2. pharmaGology of dopamine systems; and
 
3. behaviors mediated by dopamine systems.
 
Biology of Dopamlne Systems
 
Biosynthesis of Dopamine
 
The synthesis of dopamine begins when the amino acid
 
tyrosine is converted to 3,4-dihydroxyphenylalanine (DOPA)
 
by tyrosine hydroxylase (Cooper, Bloom, & Roth, 1991). The
 
next step involves the enzyme dopa decarboxylase (correctly
 
called aromatic L-amino acid decarboxylase) which
 
decarboxylates DOPA to dopamine in the cytoplasm of the
 
nerve cell (Cooper et al., 1991). The dopamine is then
 
stored in the nerve terminals until it is required for
 
release. Feedback inhibition is apparent in this system, as
 
tyrosine hydroxylase (rate-limiting substance) responds to
 
high or low levels of dopamine in the nerve terminals (Roth,
 
1979). When dopamine levels are high, tyrosine hydroxylase
 
is prevented from catalyzing the formation of dopamine
 
(Roth, 1979).
 
Storage of Dopamine
 
There is evidence to suggest that dopamine is stored in
 
more than one pool (Groppetti et al., 1977). Two distinct
 
pools with different rates of turnover have been described
 
(Nissbrandt & Carlsson, 1987). There appears to be a
 
soluble or free storage pool in the cytoplasm which is
 
important for controlling dopamine synthesis by changing the
 
activity of tyrosine hydroxylase. There is a second pool of
 
dopamine which is stored in granules (McMillen, German, &
 
Shore, 1980).
 
Release of dopamine is regulated by exocytosis from the
 
granule storage pool and is calcium dependent. Newly
 
synthesized dopamine is preferentially released while
 
previously synthesized dopamine is stored and released under
 
aversive conditions only (McMilien et al., 1980). The free
 
storage pool in the cytoplasm would first be transferred to
 
the granules before being released. The substantia nigra in
 
the rat seems to release dopamine from only one pool
 
(Nissbrandt & Carlsson, 1987).
 
Dopamine release from the striatum is also regulated by
 
cell firing rates and inhibitory autoreceptors that exist on
 
the presynaptic neuron (Carlsson, 1975; Wolf & Roth, 1990).
 
Metabolism of Dopamine
 
The two main enzymes involved in the metabolism of
 
dopamine are monoamine oxidase (MAO) and catechol-0­
methyltransferase (COMT). MAO converts dopamine to
 
3,4-dihydroxyphenylacetaldehyde which is then converted to
 
3,4-hydroxyphenylacetic acid (DOPAC). DOPAC is converted to
 
homovanillic acid (HVA) by COMT (Nissbrandt & Carlsson,
 
1987). COMT is particularly important for the extracellular
 
degradation of dopamine (Gulderg & Marsden, 1975). Reuptake
 
of dopamine into the presynaptic terminal, and not enzyme
 
degradation, is the primary method of termination for
 
dopaminergic action in the synapse (Baldessarini, 1975;
 
Iversen, 1978). The uptake of dopamine is mediated by a
 
carrier mechanism in the membrane of the presynaptic
 
terminal and cell body region (Geffen, Jessell, Cuello, &
 
Iversen, 1976; Harris & Baldessarini, 1973). A second
 
noncarrier mediated uptake system has been described
 
accounting for approximately 10-^30% of dopamine uptake
 
(Krueger, 1990). The uptake system also functions as a
 
receptor or binding site for many psychoactive compounds
 
such as tricyclic antidepressants and the psychomotor
 
stiiaulants (Bradford, 1986; Randrup & Braestrup, 1977).
 
Dopamine Receptors
 
Dopamine receptors have been divided into subtypes,
 
the first two to be classified were; Dl, which activates
 
adenylyl cyclase when stimulated; and D2 which is thought to
 
be uncoupled to adenylyl cyclase or coupiled in an inhibitory
 
manner (Kebabian, 1978; Kebabian & Calne, 1979; Spano,
 
Govini, & Trabucchi, 1978). Further research has revealed
 
D3, D4, and D5 receptors, although they have not yet been
 
fully characterized (Sokoloff/ Giros, Martres, Bouthenet, 5e
 
Schwartz, 1990; Sunahara et al., 1991; Van Tol et al.,
 
1991).
 
In the nigrostriatal system, most of the dopamine
 
receptors lie on the dendrites or on the soma of neurons
 
postsynaptic to dopamine containing neurons. In the ;
 
striatum, the Dl receptors out number D2 receptors 3 to 1
 
(Boyson, McGonigle, & Molinoff, 1984; Rao, Molinoff, &
 
Joyce, 1991).
 
Dopamine receptors have also been found presynaptically
 
on dopamine containing neurons, on somatic-dendritic regions
 
and on nerve terminals. Th(2se receptors are called
 
autoreceptors and are important in the local regulation of
 
nerve impulse flow, dopamine synthesis, and dopamine rielease
 
(Wolf & Roth, 1987). Autoreceptors are more sensitive to
 
dopamine agonists than postsynaptic receptors (Roth, 1979;
 
Wolf & Roth, 1987). Dopamine autoreceptors are thought to
 
be of the 02 receptor Subtype (Wolf & Roth, 1987), however,
 
preliminary evidence suggests that the D3 subtype may also
 
exist as an autoreceptor. Dopamine autoreceptors also
 
influence tyrosinehydroxylase activity by interfering with
 
the phosphorylation of the enzyme (Wolf & Roth, 1987).
 
Ontocenv of Dopamine Svstems
 
The dopamine systems, with its many components, are
 
typically present in the rat pup at birth. Dopamine is
 
present at 12-13% of adult levels on postnatal day (PD) 0 in
 
the striatum and slowly increases until adulthood (Coyle &
 
Henry, 1973; Ribary, Schumlpf, & Lichtensteiger, 1986).
 
Activity and conduction of dopaminergic neurons in the
 
substantia nigra to the terminal regions of the striatum are
 
evidenced on PD 0 (Tepper, Trent, & Nakamura, 1990). Neurons
 
are near or at mature rates between the third and fourth
 
postnatal weeks (Tapper et al., 1990). Release mechanisms
 
are mature at PD TO (Walters, Chapman, & Howard, 1990). MAO
 
and COMT, the degradative enzymes, can be detected at
 
gestation day (GO) 15 in the striatum (Fiszman, Zuddas,
 
Masana, Barker, & di Porzio, 1991). By GO 16, high affinity
 
dopamine uptake mechanisms are functioning (Fiszman et al.,
 
1991). Ontogenetic increases in uptake binding sites are
 
seen as early as PD 3 when binding sites reach 22% of adult
 
levels and adult levels are reached by PD 39 (Bonnet &
 
Costentin, 1989).
 
Dopamine receptors are at a low level at birth, with Dl
 
receptors at 9-14% of adult levels and D2 receptors at 9%
 
(Murrin & Zeng, 1986; Rao et al., 1991). There is
 
disagreement in the literature as to when these receptors
 
reach adult levels. Several studies have shown Dl receptor
 
levels to reach a peak between PD 28 and PD 40 and then
 
decline to adult levels (Gelbard, Teicher, Faedda,
 
Baldessarino, 1989; Giorgi et al., 1987; Rowlett, Rice,
 
McDougall, Bardo, & Pedigo, 1991). However, another study
 
suggests that adult levels for Dl receptors are reached by
 
the end of the third postnatal week (Zeng, Hyttel, & Murrin,
 
1988). Rao et al. (1991) found that Dl receptors reached
 
adult levels at PD 16, although adulthood was defined as 60
 
PD for this study; whereas, others used 70-120 PD as the
 
criteria. Adult levels for D2 receptors are reached after
 
30 to 60 postnatal days, with adulthood defined as 60-day­
olds (Murrin & Zeng, 1986; Rao et al., 1991). With D2
 
receptors there appears to be a linear increase from birth,
 
although, other results indicate that D2 receptors peak at
 
PD 40 and then decrease to adult levels (adults were defined
 
as 120-day-olds).
 
It does not appear that rat pups have functional
 
autoreceptors until PD 35. As shown by Shalaby & Spear
 
(1980), attenuation of locomotor activity does not occur to
 
low doses of apomorphine in rat pups under PD 35. Electro-

physiological studies indicate that autoreceptors do not
 
develop until at least four weeks after birth (Pitts,
 
Freeman, & Chiodo, 1990).
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Pharmacological Effects of Dopamine Systems
 
D1 and D2 receptors show different affinities for
 
endogenous dopamine, with D1 having a ten times higher
 
affinity than D2 (Hess & Creese, 1987; Seeman & Niznik,
 
1988). The recently classified dopamine receptor subtypes
 
(i.e., D3, D4, and D5) also show different affinities for
 
endogenous dopamine (Sokoloff et al., 1990; Sunahara et al.,
 
1991; Van Tol et al., 1991).
 
Recently, the development of selective and non-

selective dopamine-acting drugs has led to a rapid increase
 
in knowledge about dopamine system functioning. Specific Dl
 
receptor agonists (drugs that bind to and activate only Dl
 
receptors) include SKF 82958 (O'Boyle, Gaitanopoulous,
 
Brenner, & Waddington, 1989); whereas, partial agonists are;
 
SKF 89641 and SKF 89145 (both theinopyridines derivatives),
 
and SKF 38393 (a benzazapine compound) (Lorio, Barnett,
 
Leitz, Houser, & Korduka, 1983; Sibley, Leff, & Creese,
 
1982). A selective antagonist for the Dl receptor (drugs
 
that block Dl receptors) is SCH 23390. Specific agonists
 
for D2 receptors are quinpirole and bromocriptine;
 
antagonists include sulpiride and other benzamides (Clark &
 
White, 1987).
 
Nonselective dopamine receptor agonists (drugs that
 
bind to and activate the various dopamine receptor subtypes)
 
include: N-propylnorapomorphine (NPA), apomorphine, and
 
ADTN; whereas, nonselective antagonists include: cis(Z)-

Fliipentixol, cis{Z)-Piflutixol, and cis(Z)-Clopentixol.
 
Although apomdrphine has been widely used in research, it
 
has recently been shown to be more selective than NPA in
 
actiyating D2 than D1 receptors (Goldman & Kebabian, 1984;
 
Seeman & Grigoriadis, 1987). IIPA. and apdmorphine haye also
 
been shown to have a greater potency at presynaptic sites
 
than at postsynaptic sites (Meller, Goldstein, Friedhoff, &
 
Schweitzer, 1988).
 
EEDQ is a peptide coupling agent which noncompeti­
tively binds to dopamine receptors and depletes both D1 and
 
D2 receptors (Crawford, McDougall, Rowlett, & Bardo, 1992).
 
It has been used to determine age-dependent and regional
 
differences in dopamine receptor turnover and recovery for
 
both D1 and D2 binding sites (Battaglia, Norman, & Creese,
 
1987; Fuxe, Agnati, Pich, Meller, & Goldstein, 1987; Leff,
 
Gariano, & Creese, 1984; Norman, Battaglia, & Creese, 1987).
 
EEDQ also inactivates alpha-adrenergic, serotonin and GABA
 
receptors, however by protecting dopamine receptors,
 
behaviors mediated by dopamine can be differentiated from
 
behaviors mediated by other receptors. Receptors can be
 
protected by using specific D1 and 02 antagonists such as
 
SCH 23390 and sulpiride. These selective antagonists block
 
01 and 02 receptors, thereby eliminating EEOQ's ability to
 
inactivate those specific receptor subtypes (Henry, Joseph,
 
10
 
Kochman, & Roth, 1987; Leff et al., 1984). Studies have
 
shown that behavioral recovery is correlated with recovery
 
of dopamine receptors (Hamblin & Creese, 1983).
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Behaviors Mediated by Dopamine Systems
 
Adult studies
 
Dopamirve systems play a critical role in motor control.
 
For example, when dopamine agonists are administered to
 
rats, there is a decrease in locpmotor activity at low doses
 
and an increase in motor activity at high doses (Arnt,
 
1987). Stereotyped behaviors shch as sniffing, rearing/ and
 
head movements, as well as oral dyskinesias are produced at
 
even higher doses, A decrease in behavior is produced by
 
dopamine antagohists, including suppression of conditioned
 
responses (Arnt, 1987).
 
Dl receptors are involved in grooming, perioral
 
activity, and perhaps non^stereotyped locomotor activities
 
(Clark & White, 1987). D2 receptors are involved in
 
locomotor activity, sniffing, yawning, and rearing (Arnt,
 
Hyttel, & Perregaard, 1987; Dall' Olio, Gandolfi, Vaccheri,
 
Roncada, & Montanaro, 1988; Longoni, Spina, & DiChiara,
 
1987; Molloy & Waddington, 1985). Dl and D2 receptors
 
appear to interact to affect behavior. For example,
 
grooming behaviors mediated by Dl receptors are attenuated
 
by excessive D2 activation. In addition, Dl receptor
 
systems appear to play a 'permissive' role for D2 agonist­
induced behaviors, as Dl antagonists block the enhanced
 
sniffing, yawning, and locomotor activity induced by D2
 
agonists (Arnt, Hyttel, & Meier, 1988; Longoni et al., 1987;
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McDougall/ Arnold, & Nonneman, 1990; Pugh, p'Boyle, Molloy,
 
& Waddington, 1985; Serra, CollUj & Gessa, 1987). It also
 
appears that a functioning D2 system may be necessary for
 
activating D1 mediated grooming behavior (Gandolfi,
 
Dall'Olio, Vaccheri, Rohcada, & Montanaro, 1988; Murray &
 
Waddington, 1989). Stereotyped behaviors such as: licking,
 
biting, climbing, and gnawing are fully exhibited only after
 
treatment with a combination of D1 and D2 agonists or mixed
 
agonists (Arnt & Hyttel, 1985; Bordi & Meller, 1989; Davis,
 
Jenner, & Marsden, 1990; Longoni et al., 1987). Additive
 
effects are sometimes produced by antagonism of both 01 and
 
02 receptors (Arnt & Hyttel, 1985; McOougall, Nonneman, &
 
Crawford, 1992; Waddington, 1989). Adult-like interactions
 
of 01 and 02 receptors have also been shown in preweanling
 
rats as young as ll-days-old (McOougall et al., 1990).
 
Ontoaenetic Studies
 
Developmental studies of 01 and 02 receptors use
 
similar compounds as those used for adult rats. Quinpirole,
 
a 02 selective agonist, increases locomotor activity in both
 
11-and 17-day-old rat pups (McOougall et al., 1990). The
 
selective 01 agonist, SKR 38393, produces enhanced grooming
 
and, at high doses, increased locomotor activity (McOougall
 
et al., 1990). interactive effects of 01 and 02 receptors
 
are found when SCH 23390, a selective 01 antagonist, blocks
 
quinpirole-induced increases in locomotor activity
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(McDougall et al., 1990). Moody and Spear (1992) assessed
 
ontogenetic differences in neonatal (PD 3-4), prewe^anling
 
(PD 10-11), and weanling (PD 21-22) rats. They found age-

related responses to D1 and D2 receptor stimulation with
 
separate and combined administration of D1 and D2 agonists.
 
All ages showed increases in locomotor activity and sniffing
 
to separate and combined administrations of SKF 38393 and
 
quinpirole. Contrary to McDougall et al.'s results, adult-

typical grooming responses were only seen in weanling aged
 
rats in response to SKF 38393, due perhaps to a lower dosage
 
of SKF 38393 used by Moody and Spear. Increases in vertical
 
movements and licking were also seen only in the weanling
 
aged rats in response to quinpirole or SKF 38393 combined or
 
separately. Their results suggest that D1 and D2 receptors
 
are functually operative after agonist stimulation at even
 
early ages, although differences in blood brain barrier
 
permeability, absorption rates, and other aspects of
 
dopamine functioning do show ontogenetic changes (Moody &
 
Spear, 1992).
 
Learning studies in young rats have also provided
 
information on ontogenetic differences in response to
 
dopamine receptor agonists and antagonists. Response
 
suppression learning of yohnger (11- and 13-day-old) and
 
older (17- and 19-day-old) rat pups was compared after 02
 
receptor activity was blocked with the antagonist sulpiride
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(McDougall & Nohneman, The researchers found
 
dlfferehces in responding between the ll-and l7-da.y-pld
 
rats, as sulpiride had no effect on the 11-day-olds punished
 
responses; whereas, the punished responding of 17-day-old
 
rats was disrupted by sulpiride. These results suggest that
 
some maturation of the D2 system may occur between 11- and
 
17-days of age accounting for differences in response to
 
sulpiride (McDougall & Nonneman, 1989).
 
Recent studies have shown that rat pups do not show
 
drug sensitization until after 21 PD (Kolta, Scalzo, Ali, &
 
Holson, 1990). Habituation is a decrease in response to a
 
novel environment. Drug sensitization occurs when there is
 
an overresponiveness to a drug after repeated administra
 
tion. Drug sensitization and habituation research on 17­
day-old pups showed stable levels of activity when treatment
 
consisted of successive NPA treatment for three testing days
 
(NNN) (McDougall, Crawford, & Nonneman, 1992). However,
 
rats given saline for two days and NPA (SSN) on the third
 
testing day did exhibit higher activity levels than saline
 
subjects (SSS) and less than those in the NNN group
 
(McDougall, Crawford, & Nonneman, 1992). Habituation to the
 
chamber decreased the number of activity counts, although
 
the pattern of responding was similar for both nonhabituated
 
and habituated groups (McDougall, Crawford, & Nonneman,
 
1992). ^ ^ ,
 
15
 
Mature rats and preweartling rats differ in their
 
responses to EEDQ. McDougall, Crawford, and Nonneman (1992)
 
found that EEDQ does not attenuate the typical dopaniine
 
agonist induced behaviors such as grooming and lOCoinotor
 
behavior in young rats. Crawford et ar.. (1992) tested D1
 
and D2 binding sites for depletion after EEDQ treatment and
 
found that 17-day-oid rats showed a smaliejr relative
 
decrease of receptors (69%) when compared to adult rats (86%
 
depletion rate). In a recent experiment with 11- and 17­
day-old rat pups, it was found that although depletion of
 
receptors was similar after EEDQ treatment, full recovery
 
did not occur for the 11-day-olds even after eight days
 
(Crawford, Rowlett, McDougall, Elkins, & Bardo, 1991).
 
These results indicate that there are interesting
 
ontogenetic differences in the responses of various aged
 
rats to EEDQ. First, the behaviors of 90-day-old rats, but
 
not 17-day-olds, are affected by EEDQ (ll-day-old rats have
 
never been tested behaviorally after EEDQ). Second, 17- and
 
90-day-old rats show full receptor recovery after EEDQ
 
treatment, but 11-day-olds do not. Thus, it is unclear what
 
effect EEDQ should have on the behaviors of ll-day-old rats.
 
This proposal will further assess the behavioral effects of
 
EEDQ on 11- and 17-day-old rats.
 
The age-dependent differences in receptor
 
neurochemistry between 11- and 17-day-old rat pups leads to
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the question of whethei: ll'^day-olds should respond
 
differently to EEDQ. In studies involving learned
 
behaviors, striking age-dependent behavioral differences
 
have been observed after treatment with dopamine-acting
 
drugs (McDougall & Nonneman, 1989); however, when unlearned
 
behaviors were assessed using similar drugs, few age-

dependent differences have been reported (McDougall et al.,
 
1990). since EEDQ produces profound neurochemical
 
differences between 11- and 17-day-old rats, it is expected
 
that this will be reflected behaviorally. Since no
 
behavioral data has been obtained on ll-day-old pups over
 
time, the present investigation will establish a dose
 
response curve in 11- and 17-day-olds, as well as test NPA
 
in the ll-day-qlds for the first time- Experiment 1 will
 
involve testing various NPA dosage levels on both 11- and
 
17-day-old rat pups. Sniffing is maximally produced by
 
joint D1 and D2 stimulation and should be fully observed at
 
high doses of NPA. Locomotor activity reflects increased D2
 
receptor activation, and should be observed after lower
 
doses of NPA.
 
As stated previously, EEDQ's behavioral effects are
 
different for 17- and 90-day-old rats, as EEDQ does not
 
affect the locomotor activity and grooming of NPA-treated
 
17-day-old rats (McDougall, Crawford, & Nonneman, 1992). It
 
is possible that the lack of an EEDQ-induced effect in the
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17-day-old rats is because the behaviors assessed require
 
only a small percentage of available dopamine receptors.
 
Therefore, in Experiment 2, a high dose of NPA will be used,
 
which should produce a stereotyped sniffing response. This
 
behavior requires a full complement of dopamine receptors,
 
thus an EEDQ-induced decrease in sniffing should, therefore,
 
be observed in the 17-day-old rats. Because full receptor
 
recovery is not apparent in EEDQ treated 11-day-old rats, it
 
is uncertain how they will respond behaviorally after EEDQ
 
treatment.
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Method
 
Subjects. Animals were 80 male and female rats of
 
Harlan Sprague-Dawley descent, born and reared at California
 
State University of San Bernardino. The day of birth was
 
defined as day 0. Litters were culled to 8-10 pups at three
 
days of age. Pups were caged with dam except during experi
 
mental procedures. Assignment of subjects was random with
 
eight animals selected in each group. The colony room was
 
maintained at 28°C and kept under a 12:12 hr light;dark
 
cycle. Testing was conducted during the light phase of the
 
cycle.. .
 
Apparatus. Behavioral testing Was done in activity
 
chambers made of plywood (25 X 25 X 18 cm) with a wood floor
 
and an open top. Walls and floor were painted gray. The
 
floors were divided by black lines into four equal
 
quadrants. The testing chambers were housed in a large
 
glass-topped incubator maintained at 31 + 1°C. Clear
 
Flexiglas heated holding cages with hardwood chip bedding
 
were used to hovase pups before behavioral testing.
 
Procedure and Drugs, pifferent doses of NPA (0, 0.01,
 
0.1, 1.0, and 5.0 mg/kg) were administered 5 minutes prior
 
to observation of 11- and 17-day-old rats. Each pup was
 
tested at only one age and each pup received only one drug
 
sequence. Each subject was individually habituated to the
 
19
 
testing chamber for 20 minutes prior to injection of the
 
agonist. Locomotor activity (number of line crossings) and
 
sniffing behavior were assessed for a 20 minute testing
 
session (Test Day 1). Behaviors of the same rats were then
 
assessed after drug treatment on two subsequent test days
 
(Test Days 2 and 4). A single line^crosslng was defined as
 
the rat pup placing two front paws into an adjacent
 
quadrant. Sniffing was measured every 20 seconds during the
 
session using a time sampling technique. Sniffing was
 
defined as a head down movement, in which the nose and
 
whiskers visibly moved. Eight subjects were used in each
 
group.
 
All drugs were injected intraperitoneally (i.p.) and
 
were given at a volume of 5.0 ml/kg. NPA was obtained from
 
Research Biochemicals INC. (USA) and dissolved in saline
 
prior to injection.
 
Statistics. Two 5 X 2 univariate analyses of variance
 
(ANOVAs) with repeated measures were used for statistical
 
analysis of locomotor activity and sniffing data. The three
 
test days were analyzed as a repeated variable and dose (0,
 
0.01, 0.1, 1.0, and 5.0) was analyzed as a between factor.
 
One-way ANOVAs were used to further examine significant
 
interactions. Newman-Keuls' tests supplemented ANOVAs when
 
appropriate (p < 0.05).
 
Results
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Locoinotor Activity. A significant two-way interaetiori
 
betwean dosage level and day was found for both 11- and 17­
day-old rat pups (F(8,70) = 7.87; p <0.001 and F(8,70) ^ 
 
6V39, p< 0.001, respectively) (see Figure 1). On Day 2/
 
11-day-old pups were significantly less active after
 
treatment with 5.0 mg/kg NPA, as compared to the saline-

treated pups (p < 0.05). The effects of dose yaried
 
significantly on Days 2 and 4 for 11-day-old pups, with the
 
NPA-treated animals being in general less active; F(4,39) ­
3.286, p < 0.05 and F(4,39) - 7.503, p <0.001,
 
respectively. All dosage levels of NPA (0.01/ 0.1, 1.0 and
 
5^0 mg/kg) significantly decreased locOmotor activity in 11­
day-olds on Day 4 (p < 0.05). Saline-treated rats showed a
 
progressive increase in locomotor activity across days, due
 
possibly to maturational effects (i.e. opening of eyes),
 
F(4,39) = 99.72, p < 0.001. Surprisingly, NPA-treated pups
 
did not show a day-dependent effect.
 
Seventeen-day-old pups also displayed significant drug-

dependent differences in activity on Days 2 and 4 (F(4,39) =
 
8.243, p < 0.001 and F(4,39) = 19.284, p < 0.001,
 
respectively). When assessed across days, saline-treated
 
17-day-old rats showed a significant decline in locomotor
 
activity, perhaps due to habituation effects (p < 0.05). In
 
contrast all doses of NPA increased activity significantly
 
from Day 1 to Day 2 (p <0.05), then leyelfed off.
 
21
 
  
 
 
  
  
L
I
N
E
-
C
R
O
S
S
I
N
G
S


 
T
t
 
O
J


 
CJ
i 
O
 
CJ
1 
o
 
CJ
»

 
CJ
I

 
o
o
 
o
 
o
 
o


 
o


 
□
 o
 >
 o
 •
 
D
O
 >
 O
 •
 
O
C
JI
 
O
 O
 c
/)
t?
p®
.

 
*
*
 
*
 
*
0
0
-^
0
^
I 
Vn

 
3 
3 
3 
^
 
(Q
 t
O
 (
O
 
3
 m
 
o


 
jr
 T
T 
7
r
\
 
O
 
>


 
IQ
 I
G
 (
O
 ^
 
IQ
-
<


 
-
-
<
0
 
z
z
z
 
o
-D
 "
D
 1
3 
Z
 
O
 
>
>
>
 T
l 
G
O
 
■ 
■ ■ 
^
 
m


 
C
O


 
O
 
I 
o


 
f
O
-
-
o
>
 
>
 
o
 
o
a
 
C
O
 
+
 
C
JI
 
ro
 
ro
 
C
i4
 
<j
J
o
o
 
C
JI
O
 
C
JI
O
 
C
JI
 
o
o
 
o
o
o
o
 
FI
G
U
R
E 
1
 
M
ea
n 
nu
m
be
r 
o
f 
lin
e
-c
ro
ss
in
g
s 
fo
r 
1
1
-
an
d 
1
7
-d
a
y­
o
ld
 r
a
t 
pu
ps
 i
n
 E
xp
er
im
en
t 
1
 b
y 
NP
A 
do
sa
ge
 o
n 
ea
ch
 t
e
s
t 
da
y 
2
2
 
Sniffing. Significant main effects for day and dosage
 
were found for both 11- and 17-day-olds (F(8,70) = 5.30, £ <
 
0.001 and F(8,70) = 2.77, E < 0.010, respectively) (see
 
Figure 2). In all cases, NPA produced significantly higher
 
sniffing counts than saline; moreover, the greater doses of
 
NPA (5.0 and 1.0 mg/kg) produced significantly higher counts
 
of sniffing than the lower doses (0.01, and 0.1) for both
 
11- and 17-day-old rats (p < 0.05). For 11-day-old pups,
 
sniffing in the 5.0 mg/kg NPA group increased significantly
 
over the three testing days; whereas, all other doses showed
 
significant increases from Day 1 to Day 2 only (p < 0.05).
 
Summary. The purpose of Experiment 1 was to determine
 
the doses of NPA which produced maximal sniffing and
 
locomotor activity. Results indicated that 0.01 mg/kg NPA
 
led to the most pronounced increase in locomotor activity in
 
17-day-olds. Since NPA-treated 11-day-olds were
 
significantly less active on Days 2 and 4, compared to
 
saline-treated pups, it is more difficult to ascertain an
 
appropriate dosage level. Therefore, 0.01 mg/kg NPA was
 
chosen as the low dose in Experiment 2. Sniffing for both
 
11- and 17-day-olds was significantly enhanced by 5.0 mg/kg
 
NPA leading to its choice as the high dose for Experiment 2.
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old rat pups in Experiitient 1 by NPA dosage on each test day. 
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Experiment 2
 
It has previously been shown that EEDQ does not affect
 
NPA-induced locomotor activity in 17-day-old rat pups
 
(McDougall, Crawford, & Nonneman, 1992). It is quite
 
possible that this paradoxical effect is due to a large
 
number of spare receptors in the 17-day-old rat. Thus,
 
although EEDQ inactivates at least 65% of striatal dopamine
 
receptors in 17-day-olds (Crawford et al., 1992), it is
 
possible that a sufficient number of receptors remain to
 
mediate agonist-induced effects (see McDougall, Crawford, &
 
Nonneman, 1992). In contrast to locomotor activity, drug-

induced sniffing requires that a large percentage of D1 and
 
D2 receptors must be activated for the behavior to occur
 
(Arnt et al., 1988; Longoni et al., 1987; McDougall et al.,
 
1990). This feature suggests that sniffing should be much
 
more sensitive to EEDQ's effects. Therefore, in Experiment
 
2, the NPA-induced sniffing of 11- and 17-day-old pups was
 
assessed after EEDQ treatment. In addition, by using both a
 
high and low dose of NPA, it will be determined behaviorally
 
if there are significant ontogenetic differences in recovery
 
of dopamine D1 and D2 receptors for 11- and 17-day-old rat
 
pups.
 
Method
 
Subjects and Apparatus* Subjects were 144 male and
 
female rat pups of Harlan Sprague-Dawley descent, born and
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reared at California State University, San Bernardino.
 
Rearing conditions and apparatus were the same as in
 
Experiment 1.
 
Procedure and Drugs. Using 0.01 and 5.0 mg/kg NPA, ll­
^ud 17—day—old rats were tested for receptor recovery after
 
EEOQ treatment. Rats from both age groups were divided into
 
two conditions - protected or nonprotected condition.
 
^^ot®c:ted subjects received two injections of dopamine
 
antagonists to block receptors from EEDQ inactivation (this
 
allows assessment of nondopaminergic effects of EEDQ). Rats
 
in the protected condition were given an initial injection
 
of sulpiride (100.0 mg/kg) followed, 30 min later, by an
 
injection of SCH 23390 (1.0 mg/kg). The nonprotected rats
 
received two injections of vehicle. Thirty minutes after
 
the second injection, rats were injected with either EEDQ
 
(7.5 mg/kg) or its vehicle. (A protected/vehicle group was
 
not included, since protection has not been shown to
 
significantly affect behavior.) For each rat, behavioral
 
testing occurred 1, 2, and 4 days after initial drug
 
treatments. On each of these test days, rats were injected
 
^ith either saline or NPA (0.01 and 5.0 mg/kg). Each rat
 
was given the identical treatment three times across a four
 
day span. Five minutes after agonist treatment, locomotor
 
activity and sniffing were recorded in the same manner as in
 
Experiment 1.
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All drugs were injected i.p. and were given at a volume
 
of 5.0 ml/kg. Both sulpiride and SCH 23390 were dissolved
 
in distilled water, with the former drug requiring a small
 
volume of glacial acetic acid. EEDQ was dissolved in 95%
 
ethanol:distilled water (1:4). EEDQ (N-ethoxycarbonyl-2­
ethoxy-1,2-dihydroquinoline) was acquired from Sigma (USA).
 
Sulpiride and SCH 23390 were obtained from Research
 
Biochemicals Inc. (USA).
 
Statistics. Repeated measures 3X3X3 ANOVAs were
 
used to examine locomotor activity and sniffing. The three
 
test days were treated as a repeated variable. NPA and EEDQ
 
were separated into three levels: saline, 0.01 mg/kg, and
 
5.0 mg/kg NPA; protected/EEDQ, nonprotected/EEDQ, and
 
nonprotected/vehicle. Two- and one-way ANOVA's were used to
 
further examine significant interactions. Newman-Keuls'
 
tests supplemented ANOVAs when appropriate (p < 0.05).
 
Results
 
Locomotor Activitv. No three-way interaction was found
 
for 11-day-old pups (F(8,126) = 1.07, p > 0.05). The only
 
interaction for 11-day-olds was between NPA and day
 
(F(4,126) = 7.32, p < 0.001) (See Figure 3). A significant
 
main-effect on Day 1 was found for NPA (F(2,69) = 7.935, p <
 
0.001). Eleven-day-old pups were significantly more active
 
with the lower dose of NPA (0.01 mg/kg) than with 5.0 mg/kg
 
or saline (p < 0.05). On Day 2 (£(2,69) = 7.745, p <
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0.001), saline-treated pups showed significantly higher
 
levels of activity than 11-day-dlds treated with 5.0 mg/kg
 
NPA (e < 0.05). Higher activity counts were also produced
 
by 0.01 mg/kg NPA on Day 2, when compared with 5.0 mg/kg (p
 
< 0.05). Saline-treated rats displayed significantly higher
 
activity counts on Day 4 (F(2,69) = 12.121, p < 0.001), than
 
either 0.01 or 5.0 mg/kg NPA (p < 0.05).
 
For 11-day-olds treated with saline, significant
 
increases in activity were seen from Day 1 to Day 2 (p <
 
0.05); this increase leveled off on Day 4. Significant
 
increases in locomotor activity were also seen from Day 1 to
 
Day 2 for 11-day-olds treated with 0.01 mg/kg NPA.
 
Significant three-way interactions between NPA, EEDQ,
 
and day were found for 17-day-old pups (F(8,126) = 2.01, p <
 
0.050) (See Figure 3). Two-way interactions between EEDQ
 
and day, and NPA and day were also significant for 17-day­
olds (F(4,126) = 2.59, p < 0.040, and F(4,126) = 4.14, p <
 
0.003, respectively). Significant two-way interactions
 
between NPA and EEDQ were found on Day 2 (F(4,63) = 4.642, p
 
< 0.002) for 17-day-old pups. Activity counts of pups
 
treated with 0.01 mg/kg of NPA were significantly lower on
 
Day 2 while when in the protected/EEDQ group rather than the
 
unprotected/EEDQ or unprotected/yehicle group (p < 0.05).
 
When given 5.0 mg/kg NPA, both unprotected/EEDQ and
 
protected/EEDQ groups showed significantly lower levels of
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activity than the unprotected/vehicle group (p < 0.05). The
 
protected/EEDQ group treated with saline had significantly
 
higher counts of activity for Day 2 than the
 
unprotected/vehicle group (p < 0.05).
 
On Day 1, unprotected/EEDQ pups treated with 0.01 mg/kg
 
NPA had significantly higher locomotor activity counts than
 
saline-treated pups in the unprotected/EEDQ,
 
unprotected/vehicle, or protected/EEDQ groups; 5.0 mg/kg NPA
 
treated pups in the protected/EEDQ group also had
 
significantly lower activity counts than 0.01 mg/kg treated
 
unprotected/EEDQ pups (p < 0.05). For 17-day-old pups in
 
the unprotected/vehicle group, activity increased
 
significantly from Day 1 to Day 2 for pups in the 0.01 and
 
5.0 groups, and then leveled off (p < 0.05). Saline-treated
 
pups showed significantly lower levels of activity on Day 4
 
in all three conditions than either 0.01 or 5.0 mg/kg NPA
 
treated pups (p < 0.05). Unprotected/vehicle pups given
 
0.01 mg/kg NPA were significantly more active than
 
unprotected/EEDQ pups given 5.0 mg/kg on Day 4 (p < 0/05).
 
Sniffing. As with the locomotor activity results, 11­
day-olds showed no significant three-way interaction
 
(F(8,126) = 0.80, p > 0.05) (See Figure 4). A significant
 
two-way interaction was found for NPA by day for 11-day-olds
 
(F (4,126) = 8.60, p < 0.001). Saline-treated 11-day-old
 
pups had significantly lower levels of sniffing than either
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0.01 or 5.0mg/kg NPA (e < 0.05). On Days 2 and 4, (F(2,69)
 
=43.795, E < 0.001 and F(2,69) = 123.240, E < 0.001,
 
respectively) 5.0 mg/kg produced significant increases in
 
activity compared with 0.01 mg/kg NPA (e < 0.05).
 
Over the four testing days, there was a significant
 
increase in sniffing for 5.0 mg/kg NPA treated 11-day-olds
 
(E < 0.05); all other doses remained stable with EEDQ having
 
no significant effect.
 
Significant three-way interactions between NPA, EEDQ,
 
and day were present for the 17-day-old pups (F(8,l26) =
 
4.76, E < 0.001) (See Figure 4). Significant twO-way
 
interactions for the 17-day-olds included EEDQ by day
 
(F(4,126) = 3.73, E < 0.001), and NPA by day (F(4,126) =
 
6.52, E < 0.007). Significant interactions between EEDQ and
 
NPA were found for 17-day-old rats on Days 1 and 2 (F(4,63)
 
= 5.462, E < 0.001 and F(4,63) = 7.253, E < 0.QOl). On Day
 
1, the protected/EEDQ group had significantly more sniffing
 
counts than the unprotected/EEDQ and unprotected/vehicle
 
groups when treated with 0.01 mg/kg NPA (p < 0.05).
 
Moreover, on Day 1, treatment with 5.0 mg/kg NPA produced
 
significantly higher counts of sniffing for protected/EEDQ
 
and unprotected/EEDQ groups, compared with the
 
unprotected/vehicle group (p < 0.05). On Day 2, 0.01 mg/kg
 
produced the least amount of sniffing in unprotected/vehicle
 
pups, rather than pups in the other two conditions (p <
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0.05).
 
On all three test days, saline-treated pups had
 
significantly lower levels of sniffing in all three
 
conditions; whereas 5.0 mg/kg NPA produced the highest
 
counts, significantly higher than 0.01 mg/kg treated pups on
 
Days 1 and 4 in all three conditions (p < 0.05). On Day 2,
 
5.0 mg/kg produced significantly more sniffing counts than
 
0.01 mg/kg in the unprotected/vehicle and protected/EEDQ
 
conditions (p < 0.05). A significant increase from Day 1 to
 
Day 2 was noted for pups given 0,01 mg/kg NPA in the
 
unprotected/EEDQ condition (p < 0.05).
 
Summary. For 11-day-old pups, EEDQ did not appear to
 
affect Idcomotdr activity, as the protected/EEDQ and
 
unprotected/EEDQ conditions reflected similar patterns of
 
activity as the unprotected/vehicle condition. As in
 
Experiment 1, on Days 2 and 4 saline-treated pups showed
 
higher levels of activity than pups given either 0.01 or 5.0
 
mg/kg NPA. Sniffing of 11-day-olds was also unaffected by
 
EEDQ treatment. As in Experiment 1, 5.0 mg/kg NPA-treated
 
pups had higher levels of sniffing than 0.01 mg/kg NPA- or
 
saline-treated pups.
 
Seventeen-day-old pups' locomotor activity and sniffing
 
were affected by EEDQ treatment. When EEDQ inactivated D1
 
and D2 receptors in the unprotected/EEDQ condition,
 
locomotor activity of NPA (0.01 mg/kg) treated pups was
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enhanced on Day 2, as compared with the pups in
 
protected/EEDQ condition. Both the unprotected/EEDQ and
 
protected/EEDQ conditions had lower levels of activity on
 
Day 4 after 0.01 mg/kg and 5.0 mg/kg NPA than did pups in
 
the unprotected/vehicle condition. Sniffing data showed
 
response patterns similar to Experiment 1, with 5.0 mg/kg
 
NPA enhancing sniffing behavior significantly more than 0.01
 
mg/kg NPA. On Day 1, 5.0 mg/kg NPA produced higher sniffing
 
counts in the two EEDQ conditions (protected and
 
unprotected) than in the unprotected/vehicle condition; also
 
on Day 2, pups given 0.01 mg/kg NPA showed higher sniffing
 
counts when previously given EEDQ (protected and
 
unprotected) than if given vehicle.
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Discussion
 
In the present study, dose-dependent effects of NPA
 
were established for sniffing and locomotor activity in both
 
11- and 17-day-old pups. In Experiment 1, locomotor
 
activity of 17-day-olds was typically increased by NPA, with
 
0.01 mg/kg NPA producing the highest levels of activity.
 
For 11-day-old pups, however, NPA generally decreased
 
locomotor activity in comparison to saline-treated pups.
 
Sniffing of 11- and 17-day-olds was enhanced in a dose-

dependent fashion by NPA; 5.0 and 1.0 mg/kg produced higher
 
counts of sniffing than lower doses of NPA or saline.
 
In general, results for 17-day-old pups are consistent
 
with previous research, as NPA and quinpirole have been
 
shown to increase locomotor activity (McDougall, Crawford, &
 
Nonneman, 1992; McDougall et al., 1990). Moody and Spear
 
(1992) have shown that quinpirole increases forward
 
locomotor activity in all ages including 10- and 21-day-old
 
pups; whereas, SKF 38393-indUced increases in locomotor
 
activity which were most pronounced for 3- and 21-day-old
 
pups and sniffing was first observed at 10-days-old.
 
Combinations of quinpirole and SKF 38393 maximally increased
 
locomotor activity in 10-day-olds. Researchers have also
 
shown locomotor activity and sniffing to increase in 11-day­
olds in response to quinpirole and the nonselective dopamine
 
agonist, apomorphine (McDougall et al., 1990; Moody & Spear,
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1992; Shalaby & Spear, 1980). Importantly, these results
 
are in contrast with the results of Experiment 1, as NPA was
 
shown to have no effect on the locomotor activity of 11-day­
old pups (See Figure 1). It is likely that this discrepancy
 
is due to potency considerations, as NPA is much more potent
 
than apomorphine or quinpirole. Thus, it is possible that a
 
lower dosage is necessary to produce an increase in
 
locomotor activity in 11-day-old pups.
 
The present results indicate that lower levels of NPA,
 
compared to higher levels, increase locomotor activity in
 
17-day-olds. In general, previous findings conflict with
 
this result. McDougall, Crawford, and Nonneman (1992) found
 
increased locomotor activity with higher doses of NPA (1.0
 
compared to 0.1 mg/kg), but locomotor activity was defined
 
differently in that study and probably more reflects general
 
stereotyped behavior. Other studies have also shown that
 
higher doses of D1 and D2 agonists increase locomotor
 
activity in younger animals. For example, larger doses of
 
SKF-38393 and quinpirole typically increase forward
 
locomotion for 3-, 10-, and 21-day-old pups (Moody & Spear,
 
1992), and for 11- and 17-day-olds (McDougall et al., 1990).
 
Of course, these selective agonists are not as potent as
 
NPA. Consistent with the present results, increasing doses
 
of apomorphine were shown to decrease locomotor movements in
 
younger animals (Shalaby & Spear, 1980).
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The dose-dependent increase in NPA-induced stereotyped
 
sniffing reported here is consistent with past research, as
 
Moody and Spear (1992) found increased sniffing with higher
 
doses of SKF-38393 in 10-day-olds. Shalaby and Spear (1980)
 
also reported increased sniffing for 7- and 14-day-old pups
 
with increased apomorphine doses. Sniffing also increases
 
in ll-day-olds in response to quinpirole (McDougall,
 
Crawford, & Nonneman, 1992). Stereotyped sniffing requires
 
both D1 and D2 receptor activation, suggesting that both D1
 
and D2 receptors were fully activated for 11- and 17-day-old
 
pups.
 
Adult studies have shown that low levels of dopamine
 
agonists decrease locomotor activity (Arnt, 1987), possibly
 
due to autoreceptor activation; whereas, activation of
 
postsynaptic D1 and D2 receptors with higher doses of
 
dopamine agonists increase locomotor activity and sniffing
 
in rats (Arnt, 1987; Clark & White, 1987). It has been
 
suggested that autoreceptors do not develop in the rat until
 
after PD 35 (Shalaby & Spear, 1980). This would indicate
 
that low doses of dopamine agonists should increase
 
locomotor activity in younger rats. The present results are
 
consistent with the hypothesis that autoreceptors are not
 
present in 11- or 17-day-old rat pups. Similar to adults,
 
both 11- and 17-day-olds showed enhanced sniffing behavior
 
with higher doses of NPA, indicating that dopamine agonist­
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induced stereotyped behaviors are similar for younger rats
 
as well as adults.
 
In Experiment 2, EEDQ inactivation of D1 and D2
 
receptors was behaviorally assessed for II- and 17-day-old
 
rat pups using NPA. In general, 11- and 17-day-old pups did
 
not display aduit typical responses to EEDQ, as NPA-induced
 
behavior was not inactivated by EEDQ. McDougall, Crawford,
 
and Nonneman (1992) found similar results for 17-day-old
 
pups. Although 11-day-olds do not show full receptor
 
recovery after 8 days as do 17-day-olds, no evidence showed
 
that EEDQ affected behaviors. Both locomotor activity and
 
sniffing patterns of the pups were similar in both
 
Experiments.
 
EEDQ pretreatment paradoxically enhanced some of the
 
behaviors of 17-day-old pups. When D1 and D2 receptors were
 
inactivated by EEDQ (the unprotected/EEDQ condition)
 
locomotor activity was enhanced on Day 2 by 0.01 mg/kg NPA,
 
compared with pups whose D1 and D2 receptors were left
 
intact (protected/EEDQ). Sniffing behavior was also
 
enhanced by both EEDQ conditions (protected and
 
unprotected), as 5.0 mg/kg NPA produced higher sniffing
 
counts on Day 1, compared with the unprotected/vehicle
 
condition; 0.01 mg/kg NPA also produced increased activity
 
on Day 2 in both EEDQ pretreatment conditions. A similar
 
enhancement of locomotor activity after EEDQ induced
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receptor inaetiyation has previously been reported
 
(McDougall, Crawford, & Nonneman, 1992). One possible
 
explariation is that 01 and D2receptGrs rebover faster in
 
young rats than adults. This pdssibility appears plausible,
 
since locomotor activity enhancement did not occur until day
 
2. Although the absence of this effect oh 0^ is
 
difficult to explain. This possibility also cannot explain
 
the EEDQ-induced enhancement of sniffing on Day 1. Another
 
possibility is that the D1 and D2 receptors still
 
functioning after EEDOinaetivation are sensitized by EEDQ
 
and become hyper-responsive to NPA. Thus, the receptors
 
remaining may still be able to fully mediate behavior.
 
Although EEDQ inactivation of dopamine receptors is greater
 
for adult rats than pups (Crawford et al., 1992; Crawford et
 
al., 1991), increases in sniffing behavior two days after
 
EEDQ treatment have been reported in adult rats (Meller et
 
al., 1989). Meller et al. suggest that the enhanced
 
sniffing may be the result of a sufficient number of
 
dopamine receptors being available for sniffing behavior
 
without competing behaviors interfering.
 
A number of adult studies indicate that EEDQ treatment
 
results in a loss of responses to dopamine D2 agonists (Arnt
 
& Hyttel, 1989; Arnt et al., 1988; Hamblin & Creese, 1983;
 
Meller et al., 1989). The D2 agonist, quinpirole had no
 
effect on stereotyped behaviors after EEDQ treatment,
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indicating a sufficient depletion of D2 receptors in the
 
adults (Arnt et al., 1988). McDougall, Crawford, and
 
Nonneman (1992) also found EEDQ treatment to inhibit NPA-

induced increases in locomotor activity and decreases in
 
grooming behavior for at least two days in 90-day-old rats.
 
A number of possibilities exist for the age-dependent
 
behavioral differences in response to EEDQ treatment. One
 
possibility is that dopamine receptors may be unaffected by
 
EEDQ in the young rat. However, Crawford et al. (1992)
 
found binding sites for 17-day-old-rats to be approximately
 
69% when compared with adult rats with an 86% depletion
 
rate. This amount of inactivation should be sufficient to
 
disrupt behavior in the younger animals (McDougall,
 
Crawford, & Nonneman, 1992). Similar depletion rates are
 
found for 11-day-old pups in comparison to 17-day-olds, and
 
in contrast full recovery did not occur for the 11-day-olds
 
even after eight days (Crawford et al., 1991). Even after
 
24 hours, receptor inactivation is still apparent in the
 
younger rats, although they do show faster recovery rates
 
than older rats (Crawford et al., 1992; Crawford et al.,
 
1991; Leff et al., 1984).
 
Another possibility is that the young rat may have a
 
receptor reserve sufficiently large enough to compensate for
 
the loss of D1 and D2 receptors. Arnt et al. (1988)
 
suggests that a receptor reserve may exist for D1 mediated
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behaviors, thus explaining the lack of effect of EEDQ
 
treatment on those behaviors. However, it is unlikely that
 
11- and 17-day-old pups have an overabundance of D1 and D2
 
receptors, since these receptors are still below adult
 
levels (Murrin & Zeng, 1986; Rao et al., 1991; Rowlett et
 
al., 1989; Zeng et al., 1988). A receptor reserve
 
hypothesis also does not account for the 0.01 mg/kg NPA-

induced increases in locomotor (in the unprotected/EEDQ
 
condition) and sniffing (in both EEDQ conditions) in 17-day­
olds on Day 2; or the 5.0 mg/kg NPA-induced increase in
 
sniffing on Day 1 for the protected and unprotected/EEDQ
 
conditions, since these findings were not seen across all
 
days.
 
A last possibility is that dopamine receptors in the
 
young rat may be sensitized by EEDQ treatment, thus
 
compensating for those destroyed. Some results from
 
Experiment 2 can best be explained by this possibility,
 
since EEDQ produced higher activity levels when D1 and D2
 
receptors were inactivated on Day 2 for 17-day-old pups.
 
However, the general inability of EEDQ to inhibit NPA-

induced behaviors is still unexplained. It may be that
 
postsynaptic mechanisms are insufficient for explaining this
 
phenomenon, and EEDQ is acting at presynaptic sites to
 
produce these behaviors. Although it is known that DOPAC
 
levels are elevated in adult rats, but not rat pups, treated
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with EEDQ, few studies have assessed the possibility that
 
presynaptic sites may be responsible for the ontogenetic
 
differences in EEDQ-induced responses.
 
For both Experiments 1 and 2, day-dependent increases
 
in locomotor activity were generally observed for 17-day-old
 
pups treated with NPA. Only for the unprotected/EEDQ
 
condition did activity significantly decrease with 0.01
 
mg/kg NPA from Day 2 to Day 4. Interestingly, 11-day-olds
 
in Experiment 1 showed no increase in activity over days
 
with NPA treatment, although in Experiment 2 a significant
 
increase in activity from Day 1 to Day 2 was noted for 0.01
 
mg/kg NPA. Sniffing behavior showed day-dependent
 
increases, as 11- and 17-day-olds in Experiment 1 exhibited
 
general increases in sniffing over testing days with all
 
doses of NPA. In Experiment 2, 11-day-olds in the 5.0 mg/kg
 
NPA group showed day-dependent increases in sniffing;
 
whereas, 17-day-olds showed this increase in the
 
unprotected/vehicle condition only. As with locomotor
 
activity, the unprotected/vehicle pups had increased levels
 
of sniffing from Day 1 to Day 2 with 0.01 mg/kg NPA, which
 
then decreased on Day 4; this was also seen in the
 
protected/EEDQ condition.
 
In Experiment 1, a drug-sensitization effect appears to
 
be occurring for the 17-day-old pups in both locomotor
 
activity and sniffing, and for ll-day-old sniffing
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responses. Although some researchers have argued that
 
sensitization does riot occur in rats under PD 21 to
 
amphetamine (Kolta et al., 1990), others have observed
 
sensitization-like effects with NPA treatment in preweanling
 
rat pups (McDougall, Crawford, & Nonneman, 1992).
 
Performance of the 17^day-olds in Experiment 2 is also
 
consistent with drug-sensitization. The decrease in
 
locomotor activity and sniffing on Day 4 for NPA (0.01
 
mg/kg) treated pups in the unprotected/vehicle condition,
 
may suggest D1 and D2 receptors have been sensitized by
 
EEDQ, making it impossible for NPA to induce its normal
 
sensitizing effects.
 
EEDQ has been shown to inactivate receptor types other
 
than dopamine D1 and D2, including: alpha-adrenergic,
 
serotonin and GABA receptors (Meller, Bohmaker, Goldstein, &
 
Friedhoff, 1985; Miller, Lumpkin, Galpern, Greenblatt, &
 
Shader, 1991). By selectively protecting dopamine receptor
 
subtypes with D1 and d2 antagonists, behavioral effects due
 
to nondopaminergic receptors are assumed to be equal between
 
protected and,unprotected conditions (Hamblin & Creese,
 
1983; Henry et al., 1987; Leff et al., 1984; Meller et al.,
 
1989). Dopamine receptor subtypes D1 and D2 were
 
selectively protected by using sulpiride and SCH 23390 in
 
the current study, thus allowing dopaminergic and
 
nondopaminergic effects to be separated. As seen on Day 2,
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17-day-old pups were significantly less active in the
 
protected/EEDQ condition after 0.01 jng/kg NPA treatment, as
 
compared with the unprotected conditions, suggesting
 
nondopaminergic processes affected locomotor activity in the
 
older pups.
 
In summary, low doses of NPA increased locomotor
 
activity in 17-day-old pups; however, ll-day-old pups
 
displayed lower activity levels with NPA. It is possible
 
that 11-day-olds require a lower dose of NPA than those
 
tested here to display increases in locombtor activity.
 
Sniffing behavior was enhanced for both 11- and 17-day-olds,
 
with 5.0 mg/kg producing the most pronounced effect.
 
EEDQ pretreatment did not produce an adult-typical response
 
in either 11- or 17-day-old pups; and in some cases produced
 
an enhanced effect in 17-day-olds. These results suggest
 
that either dopamine receptors recover faster in yodng
 
animals or that a sufficient numbers of dppamine receptors
 
were left intact after EEDQ treatment to mediate these
 
behaviors.
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